Sentences with phrase «cancer society clinical»

He is a Doris Duke Distinguished Clinical Research Scientist and American Cancer Society Clinical Research Professor.

Apr 28, 2009 Charis Eng, MD, PhD selected for the American Cancer Society Clinical Research Professorship Charis Eng, MD, PhD, the Sondra J. and Stephen R. Hardis Chair of Cancer Genomic Medicine and founding Chairwoman of the Genomic Medicine Institute, has been named as the American Cancer Society (ACS) Professor of Clinical Cancer Research.

Not exact matches

«The American Society of Clinical Oncology (ASCO) applauds the U.S. Senate for their decisive vote today to pass the 21st Century Cures Act and authorize funding for the Beau Biden Cancer Moonshot and NIH Innovation Projects,» wrote the organization in a statement.

In a statement released Tuesday, the American Society of Clinical Oncology outlined research tying alcohol to two types of cancer and told Americans to drink less.

Johnson & Johnson's cancer treatment Zytiga significantly cut the death risk for newly - diagnosed, advanced prostate cancer patients by 38 %, according to data unveiled at the ongoing American Society of Clinical Oncology (ASCO) annual meeting this weekend.

BIG DATA AND CANCER: STANDARDIZATION With Mary Beckerle of the University of Utah; Clifford A. Hudis of the American Society of Clinical Oncology; Greg Simon of The White House; and Clifton Leaf of Fortune — Report by Erika Fry — Video: The Crucial Data That Will Help You Fight Cancer — Video of the entire session

Dr. Clifford A. Hudis, Chief Executive Officer, American Society of Clinical Oncology Greg Simon, Executive Director, Cancer Moonshot Task Force, The White House Dr. Ken Robert Smith, Distinguished Professor of Family Studies and Population Science; Director, Utah Population Database, University of Utah Moderator: Clifton Leaf, Fortune

Participants included CEOs Jonathan Bush of Athenahealth, Ron Gutman of HealthTap, Dr. Clifford Hudis of the American Society of Clinical Oncology, Dr. Vivian Lee of University of Utah Health Care, VitalConnect CEO Nersi Nazari, James Park of Fitbit, and Andrew Witty of GSK, as well as President of Flex Health Solutions John Carlson, Multiple Myeloma Research Foundation Founder Kathy Giusti, Dr. Sanjay Gupta, Arianna Huffington, Andreessen Horowitz General Partner Vijay Pande, Parker Foundation President Sean Parker, Women's Alzheimer's Movement Founder Maria Shriver, and White House Cancer Moonshot Task Force Executive Director Greg Simon.

In a trio of studies to be presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, investigators at Dana - Farber Cancer Institute will present the results of clinical trials showing that new drug combinations can significantly extend the time in which multiple myeloma is kept in check in patients with relapsed or treatment - resistant forms of the disease.

People diagnosed with cancer gained 3.34 million years of life thanks to cancer clinical trials run by SWOG and supported with public funds, according to new study results to be presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO), the world's largest clinical cancer research clinical trials run by SWOG and supported with public funds, according to new study results to be presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO), the world's largest clinical cancer research Clinical Oncology (ASCO), the world's largest clinical cancer research clinical cancer research meeting.

Among the changes in the American Cancer Society's updated breast cancer screening guideline is that women with an average risk of breast cancer should undergo regular, annual screening mammography beginning at age 45 years, with women having an opportunity to choose to begin annual screening as early as age 40; women 55 years and older should transition to screening every other year (vs annual), but still have the opportunity to continue with annual screening; and routine screening clinical breast examination is no longer recommended, according to an article in the October 20 issue ofCancer Society's updated breast cancer screening guideline is that women with an average risk of breast cancer should undergo regular, annual screening mammography beginning at age 45 years, with women having an opportunity to choose to begin annual screening as early as age 40; women 55 years and older should transition to screening every other year (vs annual), but still have the opportunity to continue with annual screening; and routine screening clinical breast examination is no longer recommended, according to an article in the October 20 issue ofcancer screening guideline is that women with an average risk of breast cancer should undergo regular, annual screening mammography beginning at age 45 years, with women having an opportunity to choose to begin annual screening as early as age 40; women 55 years and older should transition to screening every other year (vs annual), but still have the opportunity to continue with annual screening; and routine screening clinical breast examination is no longer recommended, according to an article in the October 20 issue ofcancer should undergo regular, annual screening mammography beginning at age 45 years, with women having an opportunity to choose to begin annual screening as early as age 40; women 55 years and older should transition to screening every other year (vs annual), but still have the opportunity to continue with annual screening; and routine screening clinical breast examination is no longer recommended, according to an article in the October 20 issue of JAMA.

Their results, published this week in the journal Biomedical Optics Express, from The Optical Society (OSA), may yield a cheaper and less invasive initial screening test for colon cancer that could complement colonoscopy, though further clinical trials will need to demonstrate the safety and effectiveness of the blood test before it is routinely used.

The results were presented during the 2017 Gastrointestinal Cancers Symposium, sponsored by the American Society of Clinical Oncology, in San Francisco.

NCIC CTG is excited to partner in the development of this clinical trial, which will be funded by a grant from the TFRI as well as grants from Canadian Cancer Society Research Institute to NCIC CTG,» says Seymour.

Results of the work are being presented at the 2017 Genitourinary Cancers Symposium (co-sponsored by the American Society of Clinical Oncology, American Society for Radiation Oncology and the Society of Urologic Oncology) in Orlando later this week.

He was relatively unknown in the NCI world, as a clinical researcher who was president - elect of the American Cancer Society (ACS), an advocacy organization founded by surgeons.

«It has to be more of an individualized approach to the type of cancer and even the patient,» says the University of Nebraska, Omaha's Julie Vose, president of the American Society of Clinical Oncology (ASCO).

Connecting a global network of more than 40,000 cancer professionals, the society serves as the leading resource for best practices in clinical oncology research and academic and community practices.

It showed effectiveness against liver cancer in a phase II clinical trial and will move into a phase III trial later this year, David Kirn, an oncologist and the company's president and chief executive officer, said at a recent meeting of the American Society for Gene & Cell Therapy in Washington, D.C..

Phase I / II clinical trial results reported at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show promising results for investigational drug brigatinib against ALK + non-small cell lung cancer (NSCLC), with 58 of 78 ALK + patients responding to treatment, including 50 of 70 patients who had progressed after previous treatment with crizotinib, the first licensed ALK inclinical trial results reported at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show promising results for investigational drug brigatinib against ALK + non-small cell lung cancer (NSCLC), with 58 of 78 ALK + patients responding to treatment, including 50 of 70 patients who had progressed after previous treatment with crizotinib, the first licensed ALK inClinical Oncology (ASCO) Annual Meeting 2015 show promising results for investigational drug brigatinib against ALK + non-small cell lung cancer (NSCLC), with 58 of 78 ALK + patients responding to treatment, including 50 of 70 patients who had progressed after previous treatment with crizotinib, the first licensed ALK inhibitor.

Combining radiation therapy with chemotherapy for patients with limited metastatic non-small cell lung cancer (NSCLC) may curb disease progression dramatically when compared to NSCLC patients who only receive chemotherapy, according to a new randomized phase II clinical trial reported today at the 59th Annual Meeting of the American Society for Radiation Oncology (ASTRO).

A comprehensive analysis of the study's results — published in June 1 online edition of the New England Journal of Medicine and to be presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago — found participants treated with enzalutamide saw an 81 percent reduction in the risk the cancer would progress and a 29 percent reduction in the risk of death.

Sylvia Adams, MD, associate professor of medical oncology at Perlmutter Cancer Center and principal investigator of this study, presented the findings on June 3 in Chicago at the annual meeting of the American Society of Clinical Oncology.

Women diagnosed with polycystic ovary syndrome — the most common hormone disorder in women of reproductive age — face a heightened risk of developing heart disease, diabetes, mental health conditions, reproductive disorders and cancer of the lining of the uterus than healthy women, according to a new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.

The blend of bacteria in the digestive tract of metastatic melanoma patients is associated with disease progression or delay in patients treated with immunotherapy, researchers at The University of Texas MD Anderson Cancer Center report at the 2017 annual meeting of the American Society of Clinical Oncology.

«Similarly 71 drugs approved by the FDA from 2002 to 2014 for solid tumours have resulted in median gains in progression - free and overall survival of only 2.5 and 2.1 months, respectively,» he says adding, «Also, only 42 per cent met the American Society of Clinical Oncology Cancer Research Committee's criteria for meaningful results for patients.»

With a newly released position paper, the American Society of Clinical Oncology (ASCO) hopes to draw attention to the strong links between drinking alcohol and risks for several types of cancer.

Researchers from Sanford Health and Chronix Biomedical today announced that results from a pilot study demonstrating the utility of a new cancer panel to detect previously undetected viral and cancer mutations are to be reported in a poster presentation titled «Detection of novel HPV mutations and chromosomal number imbalance (CNI) in oropharyngeal and laryngeal cancer using next - generation sequencing (NGS)» at the American Society of Clinical Oncology Annual Meeting (ASCO 2014) being held from May 30 through June 3, 2014 in Chicago.

Significant improvement with the use of a combination drug therapy for recurrent ovarian cancer was reported at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago today.

A study presented at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) describes the results of a phase I clinical trial of the investigational agent DMOT4039A against pancreatic and ovarian Clinical Oncology (ASCO) describes the results of a phase I clinical trial of the investigational agent DMOT4039A against pancreatic and ovarian clinical trial of the investigational agent DMOT4039A against pancreatic and ovarian cancers.

Those findings are among results of six studies of investigational chimeric antigen receptor (CAR) T cells for both adult and pediatric leukemias, adult lymphomas, and ovarian cancer which will be presented during the 2016 American Society of Clinical Oncology Annual Meeting.

New research on innovative immunotherapies for advanced or high - risk melanoma and cervical cancer were presented today at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO).

In a presentation of early clinical trial data to the 20th Annual Scientific Meeting of the Society for Neuro - Oncology, physician scientists from the University of New Mexico Comprehensive Cancer Center reported that a large number of study participants responded well to the drug combination.

The research, funded by the National Institutes of Health, the American Cancer Society, and the Cancer Prevention Research Institute of Texas, is published in The Journal of Clinical Investigation.

The study results were published online June 1 by the journal Breast Cancer Research and Treatment, and were presented June 4 at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.

As part of our coverage of the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2 — 6 in Chicago, we are speaking with Gordon Mills, MD, PhD, chair of the department of systems biology and professor of medicine and immunology at the University of Texas MD Anderson Cancer Center in Houston, about ways to incorporate homologous recombination markers into clinical practice for ovarianClinical Oncology (ASCO) Annual Meeting, held June 2 — 6 in Chicago, we are speaking with Gordon Mills, MD, PhD, chair of the department of systems biology and professor of medicine and immunology at the University of Texas MD Anderson Cancer Center in Houston, about ways to incorporate homologous recombination markers into clinical practice for ovarian cCancer Center in Houston, about ways to incorporate homologous recombination markers into clinical practice for ovarianclinical practice for ovarian cancercancer.

Society for Immunotherapy of Cancer (SITC) Symposium Combination Cancer Immunotherapy: Expanding Clinical Success Saturday, May 5, 8:00 AM — 10:00 AM, Room 12AB Chairs: Bernard A. Fox, Earle A. Chiles Res.

Though there is still disagreement, a new study presented at the American Society of Clinical Oncology (ASCO) Breast Cancer Symposium in San Francisco suggests that annual mammography and palpation of breast masses remain critical tools in early breast cancer diagCancer Symposium in San Francisco suggests that annual mammography and palpation of breast masses remain critical tools in early breast cancer diagcancer diagnosis.

Patients with metastatic castration - resistant prostate cancer (CRPC) had higher prostate - specific antigen (PSA) response when treated with enzalutamide compared with abiraterone / prednisone, but had no difference in time to progression or time to PSA progression, according to the results of a study (abstract 5002) presented by Kim N. Chi, MD, of the British Columbia Cancer Agency in Vancouver, at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2 &mdacancer (CRPC) had higher prostate - specific antigen (PSA) response when treated with enzalutamide compared with abiraterone / prednisone, but had no difference in time to progression or time to PSA progression, according to the results of a study (abstract 5002) presented by Kim N. Chi, MD, of the British Columbia Cancer Agency in Vancouver, at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2 &mdaCancer Agency in Vancouver, at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2 — 6.

A randomized, phase II trial showed improved progression - free survival in small - cell lung cancer with maintenance sunitinib vs placebo following standard chemotherapy, according to results presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

Based on our findings, the occurrence of cancer is much higher in adults over 75 years of age compared with the proportion of patients in this age group who enroll in clinical trials,» said lead study author Bindu Kanapuru, MD, medical officer in the Division of Hematology Products, Office of Hematology and Oncology Products in the US Food and Drug Administration's (FDA) Center for Drug Evaluation and Research, who presented the results at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition, held December 9 — 12 in Atlanta.

Susan has been a member of the California Department of Health Master Plan Task Force on Breast and Cervical Cancer, the American Cancer Society Subgroup Evaluating Clinical Breast Exam, the National Quality Forum Committee on Consumer Based Measurements of Mammography Centers, and the Quality Care Advisory Board of the National Breast Cancer Coalition.

Cancer Network presents exclusive coverage on ovarian cancer from the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, with reports on the latest clinical research changing the way ovarian cancer patients are being managed and trCancer Network presents exclusive coverage on ovarian cancer from the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, with reports on the latest clinical research changing the way ovarian cancer patients are being managed and trcancer from the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, with reports on the latest clinical research changing the way ovarian cancer patients are being managed and Clinical Oncology (ASCO) Annual Meeting, with reports on the latest clinical research changing the way ovarian cancer patients are being managed and clinical research changing the way ovarian cancer patients are being managed and trcancer patients are being managed and treated.

«Upfront surgery aiming at macroscopic complete resection is the goal in patients with primary advanced ovarian cancer,» said Philipp Harter, MD, PhD, of the Kliniken Essen - Mitte in Germany, during his presentation of the LION study (abstract 5500) at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.

The primary tumor location was an independent prognostic marker in patients with RAS wild - type metastatic colorectal cancer after adjusting for age, gender, synchronous / metachronous disease, consensus molecular subtype, and microsatellite instability and molecular status, according to the results of an analysis (abstract 3503) of data from CALGB / SWOG 80405 presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.

CAR T - cell therapy was also named as the American Society of Clinical Oncology's Advance of the Year in its Clinical Cancer Advances 2018: ASCO's Annual Report on Progress Against Cancer.

Dr. Karen Reckamp talks about ways to incorporate biomarkers for the treatment of lung cancer with immunotherapy into clinical practice at the 2017 American Society of Clinical Oncology Annual Meeting, held June 2 — 6 in clinical practice at the 2017 American Society of Clinical Oncology Annual Meeting, held June 2 — 6 in Clinical Oncology Annual Meeting, held June 2 — 6 in Chicago.

In addition, our cancer care program has been recognized by the Quality Oncology Practice Initiative (QOPI ®), an affiliate of the American Society of Clinical Oncology.

Cancer Network presents exclusive coverage of the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.

The report cited a survey by the American Society of Clinical Oncology that found 90 percent of Americans say cancer drugs are too costly.